AntiCancer Defends Validity Of Cancer Imaging Patents

Law360, New York (February 23, 2010, 2:55 PM EST) -- In its patent infringement suit over technology to track cancer growth, AntiCancer Inc. has fired back at Cambridge Research & Instrumentation Inc.’s counterclaims that the asserted patents are anticipated by prior art.

AntiCancer filed a motion for summary judgment Monday in the U.S. District Court for the Southern District of California, arguing that CRI’s invalidity defense is baseless.

“After three ... years of litigation, CRI has effectively admitted it has no bona fide evidence of invalidity,” the motion said. “Its ... admissions are fatal. A trial...
To view the full article, register now.